These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9142964)

  • 41. New aromatase inhibitors in the treatment of advanced breast cancer.
    Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M
    Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
    Buzdar A
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S82-4. PubMed ID: 11056331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
    Lønning PE
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progression of endocrine therapies for breast cancer: where are we headed?
    Arnedos M; Smith I
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1651-64. PubMed ID: 18020931
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM
    Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Aromatase inhibitors].
    Feutrie ML; Bonneterre J
    Bull Cancer; 1999 Oct; 86(10):821-7. PubMed ID: 10572233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
    Kvinnsland S; Anker G; Dirix LY; Bonneterre J; Prove AM; Wilking N; Lobelle JP; Mariani O; di Salle E; Polli A; Massimini G
    Eur J Cancer; 2000 May; 36(8):976-82. PubMed ID: 10885600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU
    Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
    Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
    Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Controversies in endocrine therapy for breast cancer].
    Kawakami M; Saji S; Toi M
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):181-7. PubMed ID: 14997748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
    Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
    Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
    Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
    Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
    Lønning PE
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):12-5. PubMed ID: 9741783
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Endocrine therapy for advanced or recurrent breast cancer].
    Sonoo H; Kurebayashi J
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):909-16. PubMed ID: 11478139
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.